Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULAR vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Management of hypertension, alone or in combination with other antihypertensive agents
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
10-20 mg orally once daily; maximum 60 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal half-life of 24-50 hours, mean ~34 hours; extended in elderly and hepatic impairment, dose adjustment may be needed
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Extensively metabolized in the liver via CYP3A4; undergoes first-pass metabolism. Metabolites are inactive.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: 50-60% as metabolites, 10% as unchanged drug; Fecal: ~35%; Biliary: <5%
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
>95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
92-98% bound to plasma proteins (primarily albumin)
3-10 L/kg; extensive tissue distribution, slow equilibration
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: 65-90% (first-pass metabolism); extended-release formulation provides consistent absorption
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initiate at 5 mg once daily.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A: 5 mg once daily. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established; no approved dosing.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity and risk of hypotension.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None
No FDA black box warning.
Increased angina and/or myocardial infarction upon initiation or dose titration; caution in patients with heart failure, aortic stenosis, or significant left ventricular dysfunction; may cause hypotension; caution in patients with hepatic impairment; grapefruit juice increases nisoldipine levels and should be avoided; drug interactions with CYP3A4 inhibitors and inducers.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to nisoldipine or any dihydropyridine calcium channel blocker; concomitant administration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir).
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice as they increase nisoldipine serum concentrations by inhibiting CYP3A4 metabolism. Concomitant intake of high-fat meals (e.g., >50% fat) can increase the rate and extent of absorption; advise taking consistently with or without food. St. John's wort may reduce efficacy due to CYP3A4 induction.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Pregnancy Category C. First trimester: No adequate studies; potential for fetal harm based on animal data. Second and third trimesters: Risk of fetal hypotension, oligohydramnios, and neonatal renal failure. Avoid use during pregnancy unless benefit outweighs risk.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Excreted in human milk; M/P ratio unknown. Effects on infant unknown. Use with caution, especially in preterm infants or those with compromised renal function.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Increased plasma volume and hepatic metabolism in pregnancy may require dose increase. Monitor clinical response and titrate accordingly.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Nisoldipine (Sular) is a dihydropyridine calcium channel blocker with high vascular selectivity; avoid use in patients with unstable angina or recent MI due to reflex tachycardia risk. Do not administer with grapefruit juice as it significantly increases drug exposure. Monitor for peripheral edema, especially in the elderly. Use cautiously in patients with severe aortic stenosis or hepatic impairment. May be taken without regard to meals, but avoid high-fat meals which can increase absorption.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take exactly as prescribed; do not crush or chew extended-release tablets.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not stop abruptly without consulting your doctor; may worsen chest pain or blood pressure.,You may experience dizziness or lightheadedness; rise slowly from sitting or lying positions.,Notify your doctor if you develop swelling in your ankles or feet, rapid heartbeat, or severe dizziness.,Avoid alcohol as it can increase the risk of low blood pressure and dizziness.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULAR vs AFEDITAB CR, answered by our medical review team.
SULAR is a Calcium Channel Blocker that works by Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULAR and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULAR is: 10-20 mg orally once daily; maximum 60 mg/day.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULAR and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULAR is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; potential for fetal harm based on animal data. Second and third trimesters: Risk of fetal hypotension, oligohydramnios, . AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.